PRINSTON PHARMACEUTICAL ANNOUNCES THE APPROVAL OF GENERIC WELLBUTRIN SR ® EXTENDED-RELEASE TABLETS IN THE UNITED STATES
CRANBURY, NJ – May 26, 2015 – Prinston Pharmaceutical, Inc. is proud to announce that the U.S. Food and Drug Administration (FDA) have approved its generic equivalent of Wellbutrin SR® (Bupropion SR Extended-Release Tablets USP), 100 mg, 150 mg and 200 mg. Solco Healthcare, LLC, Prinston’s generic division will be launching this product in July 2015.
"The approval of Bupropion Extended-release tablets is our second approval for 2015 that incorporates Prinston’s extended-release technologies and our third ANDA approval this year", said Jun Du, President and Chief Executive Officer of Prinston.
According to IMS Health (NSP), U.S. brand and generic sales of bupropion extended-release tablets products were approximately $170.3 million for the 12 months ending in April 2015.
About Prinston Pharmaceutical, Inc. Prinston Pharmaceutical, Inc. is a fast growing, emerging global pharmaceutical company, located in Cranbury, New Jersey, USA. We are a fully integrated pharmaceutical company engaged in product development, product registration, manufacturing, marketing and sales of high quality affordable generic prescription products to our customers. Our highly experienced R&D team meets market needs through innovation, rapidly bringing high quality products to the US market, to help patients get the best pharmaceutical products at an affordable cost. We deliver and maintain the highest quality standard and integrity in all of our products, which are manufactured by the company or its partners around the world in world-class cGMP (current Good Manufacturing Practices) manufacturing facilities.Tweet